Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1345 • ACR Convergence 2024
Long-term Changes in Coronary Calcium Score Levels Among Patients with Rheumatoid Arthritis: A Cohort Study
Cristina Corrales Selaya¹, Nuria Vegas Revenga², Carmen Secada Gómez³, Jose Antonio parra-Blanco⁴, Virginia Portilla-González⁴, Ricardo Blanco-Alonso⁵, Miguel Angel Gonzalez-Gay⁶, ivan Ferraz-Amaro⁷ and alfonso Corrales-Martínez⁸, ¹Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, ²Hospital Galdakao- Usansolo, Galdakao, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁶University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁸Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of subclinical cardiovascular (CV) disease and, consequently, a higher incidence of CV events, compared to the…
Abstract Number: 1361 • ACR Convergence 2024
The Effect of Disease Activity on Cardiovascular Risk Varies According to Rheumatoid Factor and Anticitrullinated Protein Antibody Status in Patients with Rheumatoid Arthritis
George Karpouzas¹, Virginia Pascual Ramos², Elena Myasoedova³, Miguel Angel Gonzalez-Gay⁴, alfonso Corrales-Martínez⁵, Solbritt Rantapaa-Dahlqvist⁶, Petros Sfikakis⁷, Patrick Dessein⁸, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawy¹¹, Piet Van RIel¹², Irazu Contreras Yanez¹³, Iris Jazmín Colunga Pedraza¹⁴, Dionicio Galarza-Delgado¹⁵, jose Ramon Azpiri-Lopez¹⁶, Anne Grete Semb¹⁷, Durga P Misra¹⁸, Patrick Durez¹⁹, Brian Bridal Logstrup²⁰, Ellen Margrethe Hauge²¹, George Kitas²² and Sarah Ormseth²³, and ATACC-RA, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ³Mayo Clinic, Rochester, MN, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁶Umeå University, Umeå, Sweden, ⁷Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁸University of Witwatersrand, Johannesburg, South Africa, ⁹University of Witwatersrand, Johanessburg, South Africa, ¹⁰University of Mannitoba, Winnipeg, Canada, ¹¹University of Mannitoba, Winnipeg, MB, Canada, ¹²Radboud University Medical Center, Nijmegen, Netherlands, ¹³Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁵UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ¹⁶Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁷Diakonhjemmet Hospital, Oslo, Norway, ¹⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁹UCLouvain, Louvain, Belgium, ²⁰University of Aarhus, Aarhus, Denmark, ²¹Aarhus Universitetshospital, Aarhus, Denmark, ²²The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, ²³The Lundquist Institute, Torrance, CA
Background/Purpose: Rheumatoid arthritis (RA) activity associates with cardiovascular (CV) risk. Anticitrullinated protein antibodies (ACPA) were linked to higher activity and lower remission rates. Treatment responses…
Abstract Number: 1377 • ACR Convergence 2024
Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases
Adrián Quevedo-Rodríguez¹, Lucia Otero-Varela², Fernando Sánchez-Alonso³, Yanira Pérez-Vera¹, Javier Manero-Ruiz⁴, Cristina Campos-Fernández⁵, Sara Manrique-Arija⁶, Paloma Vela-Casasempere⁷, Antonio Mera-Varela⁸, César Díaz⁹, Atusa Movasat¹⁰, Blanca Garcia-Magallon¹¹, Inmaculada Ros-Vilamajó¹², Carolina Perez-Garcia¹³ and Isabel Castrejon¹⁴, and BIOBADASER working group., ¹Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Spain, ⁴Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁵Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ⁶Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, ⁷Hospital General Universitario Alicante, Alicante, Spain, ⁸Department of Rheumatology. Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Universitario Príncipe de Asturias, Madrid, Spain, ¹¹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, ¹²Hospital Universitari Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain, ¹³Hospital del Mar, Barcelona, Spain, ¹⁴Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain
Background/Purpose: Biologic and targeted synthetic disease-modifying drugs (b/tsDMARDs) have changed the way rheumatoid arthritis (RA) is managed in recent years. Still, some patients remain symptomatic…
Abstract Number: 1394 • ACR Convergence 2024
Nationwide Retrospective Cohort Study on Clinical Outcomes in Rheumatoid Arthritis Patients Treated with JAK Inhibitors
Yurilu Gonzalez Moret¹, Diego Lema² and Fabian Rodriguez Quinonez³, ¹Jefferson Einstein Hospital, Philadelphia, PA, ²Universidad Central de Venezuela, University of Wisconsin, Philadelphia, PA, ³Einstein Medical Center Philadelphia, Philadelphia, PA
Background/Purpose: Janus kinase inhibitors (JAKi) are a class of disease activity-modifying drugs (DMARDs) that have quickly established a role in managing rheumatoid arthritis. Inhibition of…
Abstract Number: 1662 • ACR Convergence 2024
Using Circulating Soluble Serum Mediator Profiles to Understand the Mechanisms Driving Disease Flare and Drug-free Remission in Rheumatoid Arthritis
Amy Anderson¹, Fiona Rayner², Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Jasmine Sim¹, Andrew Melville³, Stefan Siebert³, Iain McInnes⁴, Carl Goodyear³, Catharien Hilkens¹, Andrew Filer⁵, Karim Raza⁵, Christopher Buckley⁶, Kenneth Baker¹, Arthur Pratt² and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ³School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁵Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁶Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Little is known of the factors that trigger disease relapses/flares in patients with rheumatoid arthritis (RA). The underpinning mechanisms have been difficult to study…
Abstract Number: 1744 • ACR Convergence 2024
Artificial Intelligence: A Novel Tool in the Belt for Improving Rheumatoid Arthritis Outcomes in the National Health Service, United Kingdom
Urwah Ahmed¹, Katharine Kalap² and Hilary Johnson³, ¹Gloucestershire Hospitals NHS Foundation Trust, Aylesbury, United Kingdom, ²Princeton University, Princeton, ³Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom
Background/Purpose: Earlier diagnosis and treatment of Rheumatoid Arthritis (RA) improve patient outcomes including pain, disability and overall mortality (NICE, 2024). The National Institute for Health…
Abstract Number: 1874 • ACR Convergence 2024
Validation Analysis of the Expanded Risk Score for Rheumatoid Arthritis in a Multicentre Italian Cohort
Fabio Cacciapaglia¹, Gian Luca Erre², Matteo Piga³, Elena Bartoloni Bocci⁴, Andreina Manfredi⁵, Ennio Giulio Favalli⁶, Maria Sole Chimenti⁷, Serena Guiducci⁸, Eleonora Celletti⁹, Addolorata Corrado¹⁰, Alessandro Giollo¹¹, SIMONE PARISI¹², Ivan Giovannini¹³, Elisa Gremese¹⁴, Francesca Romana Spinelli¹⁵, Garifallia Sakellariou¹⁶, Ombretta Viapiana¹⁷ and Fabiola Atzeni¹⁸, and Cardiovascular Obesity and Rheumatic DISeases Study Group of the Italian Society of Rheumatology, ¹Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ²Rheumatology Unit - University of Sassari, Sassari, Italy, ³Rheumatology Unit - Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy, ⁴Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ⁵University of Modena and Reggio Emilia, Modena, ⁶ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ⁷Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Roma, Italy, ⁸University of Florence, Pistoia, Italy, ⁹Medical Clinic, SS. Annunziata Hospital of Chieti, Department of Medicine and Science of Aging, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy, ¹⁰Rheumatology Unit, University of Foggia, Foggia, Italy, ¹¹Azienda Ospedale Università Padova, Padova, Padua, Italy, ¹²Rheumatology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, TURIN, Italy, ¹³Azienda Sanitaria Universitaria Friuli Centrale, Udine, Udine, Italy, ¹⁴Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁵Sapienza University of Rome, Rome - Italy, Roma, Rome, Italy, ¹⁶Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia,, Pavia, Italy, ¹⁷Rheumatology Unit, University of Verona, Verona, Italy, ¹⁸University of Messina, Italy, Messina, Italy
Background/Purpose: This study aimed to compare the performance of three validated algorithms for 10-year global cardiovascular risk stratification (GCVR): the European Systemic Coronary Risk (SCORE-2)…
Abstract Number: 1955 • ACR Convergence 2024
Ultrasound for Screening of Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review and Meta Analysis
Ikwinder Preet Kaur¹, Karishma Ramsubeik², Thway Myant³, Luis Sanchez-Ramos⁴, Laurie Ramrattan⁵ and Gurjit Kaeley⁶, ¹University of Florida College of Medicine, Jacksonville, FL, ²Baptist Health, Jax, FL, ³UF Jacksonville, Mia, FL, ⁴University of Florida college of Medicine, Jacksonville, ⁵University of Florida, Jacksonville, FL, ⁶UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: Clinically significant Interstitial Lung Disease (ILD) can occur in up to 10 percent of Rheumatoid Arthritis (RA) patients, which is associated with considerable morbidity…
Abstract Number: 2168 • ACR Convergence 2024
Two Year Data on Quality of Life, Pain and Mobility Scores After Rituximab Treatment in the Preclinical Phase of Rheumatoid Arthritis
Giulia Frazzei¹, Sophie Cramer¹, Robert Landewé², Karen Maijer³, Danielle Gerlag⁴, Paul Tak, MD PhD⁵, Niek De Vries⁶, Lisa van Baarsen⁶, Ronald Van Vollenhoven⁷ and Sander Tas⁸, ¹Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands, ²Amsterdam University Medical Center, Meerssen, Netherlands, ³Tergooi Hospital, Hilversum, Amsterdam, Netherlands, ⁴UCB, Cambridge, United Kingdom, ⁵Candel Therapeutics, Cambridge, United Kingdom, ⁶Amsterdam UMC, Amsterdam, Netherlands, ⁷Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: Over the past 10 years, several trials have investigated prevention of rheumatoid arthritis (RA) by disease modifying antirheumatic drug (DMARD) therapies. Early treatment of…
Abstract Number: 2225 • ACR Convergence 2024
Role of Fatigue in Difficult to Treat Rheumatoid Arthritis
Maria Rodriguez-Laguna¹, Leticia Leon², Dalifer Freites Nuñez³, Cristina Hormigos-martin⁴, jose otazu Moudelle⁴, Alfredo Madrid García⁵, Benjamin fernandez-Gutierrez² and lydia Abasolo Alcazar⁶, ¹Resident in Rheumatology, Madrid, Spain, ²Hospital Clinico San Carlos, Madrid, Spain, ³Hospital Clínico San Carlos. Madrid. Spain., Madrid, Spain, ⁴Hospital Clínico San Carlos, madrid, Spain, ⁵Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IDISCC), Madrid, Madrid, Spain, ⁶IdISSC. HCSC, Madrid, Spain
Background/Purpose: A subset of patients with rheumatoid arthritis (RA) who remains symptomatic after failing to multiple therapies are deemed to have "difficult-to-treat" (D2T RA). Fatigue…
Abstract Number: 2241 • ACR Convergence 2024
Associations Between Disease Activity, Physical Function and Anti-rheumatic Medications with All-cause Mortality in Rheumatoid Arthritis (RA): Data from a Canadian RA Registry
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Bindee Kuriya³, Sibel Aydin⁴, Ed Keystone⁵, Janet Pope⁶ and Claire Bombardier⁷, and OBRI investigators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²UHN, Toronto, ON, Canada, ³University of Toronto - Toronto, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁶University of Western Ontario, London, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of hospitalizations and mortality due to RA itself, associated comorbidities, and treatment-related complications. The purpose…
Abstract Number: 2261 • ACR Convergence 2024
Risk of Cervical Intraepithelial Neoplasia During Janus Kinase (JAK) Inhibitor Treatment in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Mi-Ra Cho¹, Young-Eun Kim², Yeo-Jin Lee³, Soo Min Ahn², Seokchan Hong¹, Ji Seon Oh¹, Chang-Keun Lee¹, Bin Yoo¹ and Yong-Gil Kim¹, ¹Asan Medical Center, Seoul, Republic of Korea, ²Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea, ³Asan medical center, Seoul, South Korea
Background/Purpose: Janus kinase (JAK) inhibitors are increasingly used in the treatment of Rheumatoid arthritis (RA); however, concerns have been raised about their potential to elevate…
Abstract Number: 2279 • ACR Convergence 2024
Discontinuation Pattern of Glucocorticoids in Patients with Rheumatoid Arthritis Initiating Biologics or Targeted Synthetic DMARDs in Routine Care
Isabel Castrejon¹, Lucia Otero-Varela², José María Álvaro-Gracia³, Jerusalem Calvo Gutierrez⁴, Cristina Campos-Fernández⁵, Alicia García Dorta⁶, Ana Perez⁷, DOLORES RUIZ MONTESINO⁸ and Fernando Sánchez-Alonso⁹, and on behalf of BIOBADASER, ¹Hospital General Universitario Gregorio Marañon, Madrid, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Hospital Gregorio Marañón, Madrid, Spain, ⁴HU Reina Sofia, Cordoba, Spain, ⁵Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ⁶Rheumatologist, La Laguna, Spain, ⁷Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, ⁸Hospital Virgen Macarena, Sevilla, Spain, ⁹Sociedad Española de Reumatología, Madrid, Spain
Background/Purpose: Glucocorticoids (GC) have a rapid effect on symptoms, but chronic exposure is associated to important adverse events. Although both EULAR and ACR guidelines (1,2),…
Abstract Number: 2542 • ACR Convergence 2024
Group 2 Innate Lymphoid Cells Aggravates Development of Inflammatory Arthritis
Anders Nguyen¹, Miriam Bollmann¹, Agnieszka Lastowska², Anna-Karin Hultgård Ekwall¹, Dietmar Zaiss³, Gary Firestein⁴ and Mattias Svensson⁵, ¹University of Gothenburg, Göteborg, Sweden, ²University of Gothenburg, Goteborg, Sweden, ³University Hospital Regensburg, Regensburg, Germany, ⁴University of California, San Diego, San Diego, CA, ⁵University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Activation of fibroblast-like synoviocytes (FLS) by immune cells drives inflammation and joint damage in rheumatoid arthritis (RA). Hence, understanding factors that induce destructive behaviors…
Abstract Number: 2671 • ACR Convergence 2024
Subcutaneous Abatacept vs Adalimumab Head-to-Head Comparison in Adults with Early, Dual Seropositive Rheumatoid Arthritis, Positive for the Shared Epitope HLA Class II Risk Alleles, and an Inadequate Response to Methotrexate: Results from a Phase 3 Trial
Michael Weinblatt¹, Paul Emery², Vivian Bykerk³, Andrew Cope⁴, Gerd Burmester⁵, Yoshiya Tanaka⁶, Gustavo Citera⁷, Peter Nash⁸, Quentin Dornic⁹, Sheila Kelly¹⁰ and Michael Maldonado⁹, ¹Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ²University of Leeds, Leeds, United Kingdom, ³Hospital For Special Surgery, New York, NY, ⁴King's College London, London, United Kingdom, ⁵Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁷Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁸Griffith University, Brisbane, Australia, ⁹Bristol Myers Squibb, Princeton, NJ, ¹⁰Bristol Myers Squibb, Doylestown, PA
Background/Purpose: For patients (pts) early in their RA disease course, with a clinical profile characterized by inadequate response to MTX (MTX-IR), high titers of ACPA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].